Characteristics of Malignant Pleural Effusion Resident CD8+ T Cells from a Heterogeneous Collection of Tumors

Rajeev Dhupar 1,2,*, Olugbenga T. Okusanya 2, Seth H. Eisenberg 2, Sara E. Monaco 3, Ayana T. Ruffin 4, Dongyan Liu 4, James D. Luketich 2, Udaí S. Kammula 5, Tullia C. Bruno 4, Michael T. Lotze 4,5,6 and Adam C. Soloﬀ 2

1 Surgical Services Division, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA
2 Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; okusanyao@upmc.edu (O.T.O.); she14@pitt.edu (S.H.E.); luketichjd@upmc.edu (J.D.L.); acs202@pitt.edu (A.C.S.)
3 Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; monacose@gmail.com
4 Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; atr30@pitt.edu (A.T.R.); dongyan@pitt.edu (D.L.); tbruno@pitt.edu (T.C.B.); lotzmt@upmc.edu (M.T.L.)
5 Department of Surgery, Division of Surgical Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; kammulasu@upmc.edu
6 Department of Bioengineering, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
* Correspondence: dhuparr2@upmc.edu

Received: 20 July 2020; Accepted: 25 August 2020; Published: 27 August 2020

Abstract: While T cell-based cancer immunotherapies have shown great promise, there remains a need to understand how individual metastatic tumor environments impart local T cell dysfunction. At advanced stages, cancers that metastasize to the pleural space can result in a malignant pleural effusion (MPE) that harbors abundant tumor and immune cells, often exceeding 10^8 leukocytes per liter. Unlike other metastatic sites, MPEs are readily and repeatedly accessible via indwelling catheters, providing an opportunity to study the interface between tumor dynamics and immunity. In the current study, we examined CD8+ T cells within MPEs collected from patients with heterogeneous primary tumors and at various stages in treatment to determine (1) if these cells possess anti-tumor activity following removal from the MPE, (2) factors in the MPE that may contribute to their dysfunction, and (3) the phenotypic changes in T cell populations that occur following ex vivo expansion. Co-cultures of CD8+ T cells with autologous CD45− tumor containing cells demonstrated cytotoxicity (p = 0.030) and IFNγ production (p = 0.003) that inversely correlated with percent of myeloid derived suppressor cells, lactate, and lactate dehydrogenase (LDH) within the MPE. Ex vivo expansion of CD8+ T cells resulted in progressive differentiation marked by distinct populations expressing decreased CD45RA, CCR7, CD127, and increased inhibitory receptors. These findings suggest that MPEs may be a source of tumor-reactive T cells and that the cellular and acellular components suppress optimal function.

Keywords: malignant pleural effusion; metastatic cancer; T cell response; tumor immunosuppression

1. Introduction

Facilitating endogenous anti-tumor activity in tumor-specific T cells is the cornerstone of multiple immunotherapy strategies to combat cancer. Checkpoint inhibitor blockade and adoptive cell transfer (ACT) therapies rely on the ability of immune cells to recognize tumor-associated antigens, including neoepitopes, and potentiate T cells to overcome tumor-mediated immunosuppression.
However, we do not have a clear understanding of which suppressive factors in the metastatic tumor environment are most critical. Studies of the microenvironment within solid tumors have implicated hypoxia [1,2], nutrient availability [3–5], suppressive cytokines [6,7], other molecules (e.g., lactate dehydrogenase (LDH) or lactate) [8,9], and immunosuppressive cell subsets such as regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and myeloid derived suppressor cells (MDSCs) [10–13]. Less is known about the impact of these factors within liquid tumor environments such as MPE and malignant ascites.

Malignant pleural effusions (MPE) occur when tumor cells have metastasized to the pleura, resulting in the unopposed collection of fluid in the thoracic cavity, and are a common occurrence in many end stage epithelial cancers. While lung and breast cancer patients represent 70–80% of treated cases, MPEs occur in patients with pancreatic, ovarian, and gastroesophageal cancers, among others. MPEs not only contain cancer cells but can also have a large number of immune cells (>10⁸/L), represented by diverse lymphoid and myeloid subsets. In malignant pleural mesothelioma, a primary tumor of the pleura, tumor samples have an immune signature of elevated Tregs and MDSCs that contribute to the anergy of tumor-infiltrating lymphocytes (TILs) and correlate with survival [14]. Notably, the functional capacity of the immune cells in mesothelioma has been demonstrated [15–17]. Nevertheless, at about 2500 cases per year in the United States, mesothelioma represents a very small burden of pleural disease when compared with over 150,000 annual MPEs in patients with advanced epithelial cancers.

The number of T cells in proximity to pleural tumor is generally quite large in MPEs, and the study of their potential functionality or conversely, of the cellular and soluble factors in the effusion that contribute to T cell quiescence, has been evolving [15,18–24]. Even with T cell directed immunotherapy, there are many hurdles the MPE environment might present for successful antitumor activity. Understanding the underlying factors that impact T cell function in an MPE are important to improving current immunotherapies. Therefore, we undertook the present study to examine the reactivity and functional capacity of CD8⁺ T cells isolated from a heterogeneous collection of MPEs of epithelial origin in response to the cellular component of MPEs containing malignant tumor cells. We demonstrate that MPE-resident CD8⁺ T cells possess cytolytic activity and IFNgamma production in response to autologous non-hematopoietic MPE cells ex-vivo after 24 h. We identified prominent immunosuppressive MDSC populations and soluble lactate and LDH as potential contributing factors to T cell dysfunction. These findings have implications for understanding the potential efficacy of T cell-targeted therapies for patients with MPEs and provides direction for future exploration of this readily accessible tumor compartment.

2. Results

2.1. The Immune Composition of MPEs is Heterogeneous and Unique from Peripheral Blood

The cohort presented consists of a variety of primary cancer types, patient ages, and prior treatments, with lung cancers being the most frequent (Table 1). MPEs were of volumes between 300–1000 mm³ and contained between 8 x 10⁷ and 2 x 10¹⁰ total cells with an average of 2.33 x 10⁹ ± 1.65 x 10⁹ cells per effusion.

Cytopathologic examination of malignant pleural effusions (MPEs) revealed broad variation in percentage of immune and non-hematopoietic cells, including tumor cells, mesothelial cells, and fibroblasts, with individual MPEs spanning a range from tumor rich to predominantly leukocytes (Figure 1a–c). To examine the immune composition of MPEs, we performed multiparametric flow cytometry to detect neutrophils (SSCHighCD15⁺), macrophages (SSCLowHLD-DR⁺CD11b⁺CD14⁺), monocytes (CD14⁺), natural killer (NK) cells (CD3⁻CD56⁺), B cells (CD3⁻CD19⁺), plasmacytoid dendritic cells (pDCs) (Lineage⁻HLD-DR⁺CD123⁺), myeloid dendritic cells (mDCs) (Lineage⁻HLA-DR⁺CD11c⁺), CD8⁺ T cells (CD3⁺CD8⁺), and CD4⁺ T cells (CD3⁺CD4⁺) from the live, CD45⁺ leukocyte population. Specimen availability precluded analysis
of samples 2 and 3, a bilateral MPE obtained from a pancreatic cancer patient, resulting in data on 10 out of 12 samples. The composition varied substantially, with individual patient's possessing immunophenotypes dominated by monocytes, CD4+ T cells, or neutrophils (Figure 1d). Notably, there was heterogeneity in the immune composition of MPEs that was not observed within the peripheral blood which consisted predominantly of neutrophils (Figure 1e). The percentage of monocytes and B cells from the peripheral blood positively correlated with those found within the MPE, although both monocytes and B cells were found at lower frequencies in the circulation (Table 2). These findings indicate that the leukocyte composition within MPEs is highly variable and does not reflect the proportion of immune subsets present within the circulation.

Table 1. Tumor types and clinical characteristics from 12 malignant pleural effusions.

| Patient | Tumor Origin | Patient Age (years) | Total Volume Collected (L)/Cellularity (cells/L) | Treatment at Drainage | Prior Treatments | Survival from Initial Drainage (days) |
|---------|--------------|---------------------|-------------------------------------------------|-----------------------|------------------|--------------------------------------|
| 1       | Ovarian      | 68                  | 1.0/8.00 × 10⁸ | olaparib               | doxorubicin, taxol | 231                    |
| 2       | Pancreatic * | 70                  | 0.7/5.63 × 10⁸ | TRX518/gemcitabine     | FOLFIRINOX; gemcitabine/nab-paclitaxel | 42                     |
| 3       | Pancreatic * | 70                  | 0.6/5.29 × 10⁸ | TRX518/gemcitabine     | FOLFIRINOX; gemcitabine/nab-paclitaxel | 42                     |
| 4       | Lung         | 62                  | 0.5/2.32 × 10⁸ | dabrafenib/tramentinib | none             | 198                    |
| 5       | Breast       | 62                  | 0.6/8.68 × 10⁸ | nab-paclitaxel/Herceptin | pertuzumab; trastuzumab; paclitaxel; anastrozole; letrozole; tamoxifen; exemestane | 185                    |
| 6       | Lung (SCLC)  | 68                  | 0.5/1.36 × 10⁸ | ipilimumab/nivolumab   | AEB1102; rovalpituzumab teserin; nivolumab; carboplatin/etoposide/topotecan | 45                     |
| 7       | Salivary     | 74                  | 0.3/6.67 × 10¹⁰| cisplatin/cyclophosphamide/doxorubicin | carboplatin/taxol; lupron; pembrolizumab | 7                      |
| 8       | Gastric      | 49                  | 0.7/2.32 × 10⁸ | paclitaxel/ramucirumab | FOLFOX; XELIRI and pembrolizumab | 13                    |
| 9       | Lung (SCC)   | 77                  | 0.5/1.85 × 10⁸ | pembrolizumab/ramucirumab | none             | 10                     |
| 10      | Lung (AC)    | 46                  | 1.0/1.02 × 10⁸ | al cetinib             | none             | 117                    |
| 11      | Lung (NEC)   | 61                  | 0.4/2.2 × 10⁸ | carboplatin/etoposide/atezolizumab | lanreotide; carboplatin/etoposide | 107                    |
| 12      | Lung (AC)    | 91                  | 0.7/2.03 × 10⁸ | none                  | none             | 8                      |

SCLC—small cell lung cancer; SCC—Squamous cell cancer; AC—adenocarcinoma; NEC—neuroendocrine carcinoma; L—liters. * Represents a single patient with bilateral malignant pleural effusions.
Figure 1. Immunophenotyping reveals heterogeneous composition of MPEs. (a) Representative images depicting MPEs rich in tumor cells, immune cells, or a mix of both within cytopathologic specimens. (b) Proportions of non-hematopoietic cells and leukocytes in MPEs, and (c) representation of tumor cells, mesothelial cells, and fibroblasts (absent) in the non-hematopoietic cell fraction of MPEs. Proportions of neutrophils (grey), macrophages (red), monocytes (pink), NK cells (orange), B cells (green), pDCs (light blue), mDCs (yellow), CD8+ T cells (purple), and CD4+ T cells (dark blue) from live, single, CD45+ leukocytes from (d) MPEs or (e) peripheral blood leukocytes (PBL) per patient were determined by multiparametric flow cytometry. (f) Population means ± SEM of immune cell subsets within MPEs and PBL.
Table 2. MPE/PBL Correlations of Immune Composition.

| Population   | MPE (mean±SEM) | PBL (mean±SEM) | Spearman r | p-Value |
|--------------|----------------|----------------|------------|---------|
| Neutrophils  | 29.24 ± 9.891  | 68.66 ± 6.462  | 0.5758     | 0.0883  |
| Macrophages  | 8.11 ± 1.874   | 5.97 ± 2.232   | 0.4667     | 0.1786  |
| Monocytes    | 15.00 ± 6.267  | 8.33 ± 3.092   | 0.8545     | 0.0029  |
| NK cells     | 2.77 ± 1.336   | 1.06 ± 0.503   | 0.1520     | 0.6738  |
| B cells      | 6.66 ± 1.947   | 4.82 ± 3.141   | 0.7576     | 0.0149  |
| pDCs         | 0.209 ± 0.176  | 0.024 ± 0.012  | −0.2330    | 0.5240  |
| mDCs         | 0.044 ± 0.013  | 0.071 ± 0.031  | −0.6123    | 0.0649  |
| CD8⁺ T cells | 11.09 ± 1.600  | 5.598 ± 1.425  | 0.1879     | 0.6073  |
| CD4⁺ T cells | 26.87 ± 7.413  | 5.445 ± 1.654  | 0.4061     | 0.2475  |

2.2. A Subset of MPE-Resident CD8⁺ T Cells Possess Tumor-Reactive Functionality Ex Vivo

Next, we examined if MPE-resident CD8⁺ T cells possess antitumor reactivity when removed from the pleural fluid. CD8⁺ T cells were utilized instead of bulk CD3⁺ T cells to circumvent potential immunosuppression by CD4⁺ Tregs which were present at high levels (≤ 10% of total T cells and ≤15% of CD4⁺ T cells). MPE-resident CD8⁺ T cells were bead-isolated, rested for 24 h in complete media supplemented with 6000 IU/mL IL-2, and subsequently co-cultured for 24 h at a 1:1 ratio with either autologous tumor containing non-hematopoietic cells from the MPE or autologous peripheral blood monocytes. The percentage of tumor cells in the CD45⁻ fraction ranged from 20–100% (Table S1). Bead enrichment yielded mostly CD8⁺ T cells with minor populations of CD4⁺ T cells and NK cells (Figure S1). This resulted in a significant increase in cell lysis and IFNγ production in the tumor containing co-culture as measured by LDH cytotoxicity assay when compared with autologous monocytes (p = 0.030 and p = 0.003, respectively; Figure 2a,b). There were varying degrees of target cell lysis, with undetectable levels of cytotoxicity in four of 12 co-cultures (Figure 2a). T cells, monocytes, or the CD45⁻ MPE fraction cultured alone produced minimal IFNγ (Figure 2b). IFNγ production varied, with five of 12 T cell co-cultures producing little to no IFNγ in the presence of autologous non-hematopoietic cell targets. Results from LDH release and IFNγ ELISA are reported in Table S1. CD137 (4-1BB) and CD134 (OX40) expression by CD8⁺ T cells following 24-h co-culture did not change significantly between the non-hematopoietic tumor containing co-cultures and monocyte controls (Figure S2). Results indicate that even with diverse disease and treatment status, a subset of patients possess MPE-derived CD8⁺ T cells which react to autologous tumor-containing target cells ex vivo.
2.3. Ex Vivo Expansion of MPE-Resident CD8+ T Cells Promotes an Exhausted Phenotype

To evaluate the effects of culture and rapid expansion of these MPE-resident CD8+ T cells (live CD45+CD3+CD4−CD8+), we employed multiparametric spectral flow cytometry to examine factors defining T cell memory (CD45RA, CCR7, CD127/IL-7Rα, CD25/IL-2R, CD95/Fas), inhibitory receptors (CD152/CTLA-4, CD223/LAG-3, CD279/PD-1, CD366/TIM-3, TIGIT), and co-stimulatory receptors (CD134/OX40, CD137/4-1BB, CD278/ICOS, CD154/CD40L). Bead-isolated MPE-resident CD8+ T cells from six patients were cultured in either 6000 IU/IL-2 or 6000 IU/IL-2 plus anti-CD3/CD28 activating microbeads (Dynabeads) at a 1:25 T cell to bead ratio for 24 h, 7 days, and 11-14 days. Anti-CD3/CD28 microbead activation resulted in substantial T cell expansion, serving as a surrogate for clinical rapid T cell expansion protocols (Figure S3). In both conditions there was a less differentiated phenotype at 24-h when compared to 7- and 11-14-day cultures. There was greater expression of CD45RA, CCR7, CD127, and lower expression of CD95 (Figure 3a). In the IL-2 only cultures, after 7 days there was significant upregulation of CD25, moderate upregulation of CD95, and decreases in all other examined factors (Figure 3b). By contrast, 7 days of culture in IL-2 plus anti-CD3/CD28 activating microbeads resulted in a significant increase in CTLA-4 and TIM-3 expression, moderate increase in CD95 expression, and downregulation of the remaining examined factors (Figure 3b).
Figure 3. Ex vivo culture promotes terminal differentiation of CD8^+ T cells from MPEs. CD8^+ T cells
were isolated via positive magnetic bead selection from six patients. T cells were cultured for 24 h, 7 days, or 11-14 days in either 6000 IU/IL-2 or 6000 IU/IL-2 and anti-CD3/CD28 activating microbeads, followed by cryopreservation, and simultaneous analysis by spectral cytometry. (a) Expression of individual markers of naïve cell state (CD45RA, CCR7, CD127) or maturation/exhaustion (CD95) in IL-2 (blue) or IL-2 and microbeads (red) treated cultures. (b) Change in expression levels of inhibitory and stimulatory co-receptors on T cells cultures in IL-2 or IL-2 and activating microbeads at day 7 compared to 24 h. t-SNE plots depicting combined data form 10,000 cells per patient per timepoint were generated for T cell cultures. Rphenograph clustering of unique subpopulations (c,d) and coding of T cells by culture timepoint at 24 h (green), 7d (blue), and 11-14d (red) (e,i) are shown for IL-2 only (top) and IL-2 with microbeads (bottom). Heatmaps depicting the distribution of Rphenograph clusters per culture timepoint are shown for (g) IL-2 and (h) IL-2 and micro bead treated cells. Heatmaps of the corresponding factors used for description of the clusters (f,j).

Because the T cell compartment within MPEs is comprised of diverse memory subsets and functional states, we employed computational analysis for unbiased identification of unique subpopulations. Compiled T cell culture data from all patients and timepoints was used to generate t-SNE plots for data reduction and illustration. When analyzed with Rphenograph in Cytofkit [25], T cells at 24 h (green), 7 days (blue), or 11–14 days (red) separate into distinct groups irrespective of treatment conditions, demonstrating the impact of prolonged culture (Figure 3c,d,g,h). T cell cultures treated with IL-2 or IL-2 plus anti-CD3/CD28 activating microbeads segregated into 17 and 19 unique subpopulations, respectively (Figure 3e,f,i,j). In T cells cultured with IL-2 alone, there was enrichment of clusters 10, 16, 6, and 2 at 24 h (10, 16, 6, 2) but this changed at day 7 when it was clusters 3, 9, 5, and 13. At day 11–14, clusters 1 and 15 become prominent and clusters 5 and 13 were conserved from day 7 (Figure 3d). Although each subpopulation is unique (Figure 3f,j), longitudinal culture results in progressive T cell alterations. There are early reductions in CD45RA, TIGIT, and LAG-3 but increased ICOS, OX40, and 4-1BB, followed by reductions in ICOS and 4-1BB. Similarly, IL-2 plus anti-CD3/CD28 activating microbeads results in the loss of clusters 3,10, 11 and 18 at 24 h but enrichment of clusters 8 and 16 after (Figure 3h). This progression is marked by early increased expression of CD95, TIM-3, and OX40 with decreased expression of CD45RA and CD40L, followed by loss of CD40L.

2.4. Acellular MPE Fluid Inhibits T Cell IFNγ Production and May Influence T Cell Phenotype

We next sought to examine the effect of the acellular component of MPE fluid on T cell function. MPE-resident CD8+ T cells were isolated and activated with anti-CD3/CD28 microbeads in the presence of IL-2, resulting in robust IFNγ production as detected by specific ELISA (Figure 4a). Co-culture of activated MPE-resident CD8+ T cells with autologous monocytes or tumor containing non-hematopoietic MPE cells did not affect IFNγ production. Notably, the anti-CD3/CD28 activated co-cultures plus 50% autologous acellular MPE fluid resulted in a significant reduction in IFNγ production (p = 0.018; Figure 4a). To investigate the acellular component of MPEs, cell-free MPE fluid was analyzed for sodium, potassium, glucose, LDH, lactate, pH, and CO2 (Table 3). There were increased levels of LDH, lactate, and glucose; reduced levels of CO2; and a basic pH when compared to normal reference values in serum. Levels of sodium within the MPE inversely correlated with both lactate and LDH (Figure 4b). We also examined the relationship between these factors and IFNγ production in these co-cultures. Interestingly, there was a positive correlation between CD8+ T cell production of IFNγ and sodium (p = 0.010) but an inverse correlation with lactate (p = 0.032) and LDH (p = 0.037; Figure 4c). These findings suggest that soluble components of the MPEs may suppress endogenous T cell function.

To further examine the relationship between the MPE environment and T cell phenotype, patients were grouped as high or low levels of sodium, lactate, and LDH (based on the median levels). Evaluation of subpopulations from the above t-SNE plots (Figure 3) identified distinct T cell phenotypes associated with both ex vivo culture conditions (Figure S4). These findings suggest that the MPE composition influences the dynamics and function of MPE resident CD8+ T cells.
Patient Tumor Origin Sodium Potassium Glucose LDH Lactate pH CO2

1 Ovarian 142 3.3 101 202 1.7 8.3 20
2 Pancreatic * 136 4.3 126 26 2.6 8.0 26
3 Pancreatic * 136 4.3 125 221 2.6 8.1 25
4 Lung 138 4.1 105 282 1.4 8.1 24
5 Breast 139 4.5 164 113 2.2 8.1 26
6 Lung (SCLC) 139 3.9 101 26 1.3 8.1 22
7 Salivary 136 3.8 80 328 2.6 8.0 33
8 Gastric 133 3.7 102 636 2.4 8.2 24
9 Lung (SCLC) 133 4.4 55 1158 4.9 8.3 24
10 Lung (AC) 133 4.0 85 739 5.7 7.9 21
11 Lung (NEC) 141 3.9 105 161 1.1 8.0 25
12 Lung (AC) 151 3.9 134 98 1.3 8.3 38

MPE Values (mean ± SEM)

- Sodium: 138.1 ± 1.5
- Potassium: 4.0 ± 0.1
- Glucose: 107 ± 8.1
- LDH: 375.8 ± 90.7
- Lactate: 2.5 ± 0.42
- pH: 8.1 ± 0.04
- CO2: 25.8 ± 1.5

Normal serum reference

- Na: 136–146
- K: 3.5–5.0
- Glucose: 70–99
- LDH: <171
- Lactate: 0.5–1.6
- pH: 7.35–7.45
- CO2: 35–45

* Represents a single patient with bilateral malignant pleural effusions.
2.5. Intra-Pleural MDSCs are Associated with Decreased Cytotoxic Function of MPE-Resident T Cells

Because immune composition may influence MPE-resident CD8\(^+\) T cell activity even after being removed from their proximity, we analyzed correlations with the previously described immune populations (Figure 1) as well as regulatory T cells (T\(_\text{regs}\)), tumor-associated macrophages (TAMs), and myeloid derived suppressor cells (MDSCs). MPE-resident CD8\(^+\) T cells were co-cultured with autologous monocyte or tumor containing non-hematopoietic cells after 24-h incubation in IL-2 or IL-2 plus anti-CD3/CD28 activating microbeads. LDH cytotoxicity and IFN\(_\gamma\) production were measured. The proportion of total MDSCs (including both M-MDSC (MHCI\(_\text{Low}\)CD11b\(^+\)CD66b\(^+\)CD14\(^+\)) and PMN-MDSC (MHCI\(_\text{Low}\)CD11b\(^+\)CD66b\(^+\)CD15\(^+\))) in the MPEs was associated with decreased target cell lysis (\(p = 0.041\); Figure 5a,c). By contrast, there was no correlation with the percentage of MDSCs in peripheral blood (\(p = 0.541\); Figure 5b,d). There was also no correlation between percent MDSC in either MPE or peripheral blood and IFN\(_\gamma\) production (Figure 5e,f). None of the remaining 11 leukocyte populations correlated with T cell function.

![Figure 5](image_url)

**Figure 5.** Intrapleural MDSCs are associated with reduced cytolytic capacity of MPE-resident CD8\(^+\) T cell. MDSCs were identified in MPE and PBL by flow cytometry as CD45\(^+\)SSC\(_\text{High}\)HLA-DR\(_\text{Low}\)CD14\(^+\) and/or CD15\(^+\) including both polymorphonuclear and monocytic subtypes. The proportion of MDSC shown as the percentage of total CD45\(^+\) leukocytes per patient are depicted for (a) MPE and (b) PBL. Spearman correlations between the percent of MDSCs in (c) MPE or (d) PBL and patient MPE-resident CD8\(^+\) T cell cytotoxicity upon co-culture with autologous non-hematopoietic MPE cells (highest value from co-cultures with either IL-2 alone [gray dots] or IL-2+anti-CD3/CD28 microbeads [black dots]). Spearman correlations between percent MDSCs in (e) MPE or (f) PBL and patient MPE-resident CD8\(^+\) T cell IFN\(_\gamma\) production upon co-culture with autologous non-hematopoietic MPE cells.
3. Discussion

Malignant pleural effusions have a high prevalence of tumor associated immune cells (up to $10^8$ T cells) that are readily and repeatedly accessible. While MPEs present a clinical problem, they also represent an opportunity to capture a broader and more reactive repertoire of T cells that are evolving against mutationally-driven neoepitope expressing tumor cells. In this study, the main findings are that eight of 12 MPEs from a heterogeneous population of cancer patients at different stages of treatment have T cells that can be activated 24 h after removal from the effusion, and this activity is possibly influenced by cellular and acellular components in the local compartment. Our finding that MPE-resident CD8$^+$ T cells can mediate cytotoxicity toward the autologous non-CD45$^+$ tumor containing fraction after only 24 h makes them a potential resource for finding a subset of tumor-specific T cells that are obtained in a minimally invasive manner. This could also be a useful screen for identifying patients that will respond to T cell targeted immunotherapies.

However, we do not know why some patients had minimal or no activation of their MPE-resident T cells in co-culture. One explanation is that not all MPEs contain tumor-specific CD8$^+$ T cells, as can be seen with solid tumor. Measurements of anti-tumor reactivity vary depending on the cancer (melanoma, uveal melanoma, lung, bladder), the method for determining tumor infiltrating lymphocyte (TIL) reactivity (IFN$\gamma$ production, CD137/4-1BB and CD134/OX40 expression), and the types of cells that are tested [26–29]. Because our sample size is small, future studies will allow us to better predict potential antitumor reactivity. Additionally, screening greater numbers of co-cultures, akin to multiple fragments of solid tumor, or pre-selecting specific populations may increase total anti-tumor reactivity [30,31]. Alternatively, because of variation in the tumor cell percentage that were present in the non-hematopoietic fraction, it is also possible that the stoichiometric presence of recognizable tumor antigens was too low to elicit significant T cell activation in some samples. Finally, there is heterogeneity in the types of cancers, systemic treatments, and clinical conditions that could impact T cell activity, which mimics clinical practice. Further investigation is needed to determine if there is a subset of MPE-resident T cells that are similar to traditional TIL.

Overcoming the immunosuppressive factors of the host is critical in potentiating immunotherapies. Tregs, TAMs, and MDSCs are important contributors to the immunosuppressive tumor environment, and may play a role in pleural effusions [6,7,32,33]. Immunosuppressive cell populations were present within all 12 MPEs, but only the numbers of MDSCs correlated with the activation potential of CD8$^+$ T cells in our series. Interestingly, MDSC-associated immunosuppression was observed after T cells were removed from their proximity in the MPE, suggesting that either MDSCs or factors associated with a MDSC-rich environment may impart lasting T cell dysfunction, perhaps through induced epigenetic effects. In addition to cellular suppression, an inhospitable environment plays a critical role in T cell biology that can lead to effector dysfunction [34]. Subsequently, we examined several molecules in the acellular fraction of MPEs to determine if there are derangements that may impact effector T cell activity. Our finding that sodium, LDH, and lactate levels correlate with activated CD8$^+$ T cell IFN$\gamma$ production is not surprising. Both LDH and lactate are markers of suppression and have been suggested to inhibit T cell migration and limit cytolytic function [9,35–37]. Additionally, sodium has been implicated in inhibiting the immunosuppressive function of Tregs, however its role on CD8$^+$ T cells is not well understood [38–40]. Though we found potential relationships with these three molecules, there is likely a complex interplay of many factors that contribute to the T cell dysfunction that we have not fully defined.

Because there is a low number of TILs obtained in solid tumors, these cells require expansion of roughly 800-fold to be utilized in ACT therapies, which can have several drawbacks [41–43]. Post-expansion TIL have been found to express markers suggestive of a more differentiated phenotype and an “activated state” after expansion [44,45]. A recent study examining TCR$\gamma$ chain diversity in TIL from pancreatic ductal adenocarcinoma and melanoma demonstrated that ex vivo culture of TIL in rapid expansion protocols (REP) reduced diversity, and that expanded clonotypes present post-REP did not represent the same dominant clones identified within pre-expanded TIL cultures [46]. This work
suggests that tumor antigen-specific TIL, likely the CD8+ PD-1+ subset, have decreased replicative fitness during ex vivo expansion due to their exhausted nature, and are thus out-competed by less differentiated clonotypes that lack tumor-specificity. The MPE-resident T cells that underwent culture and expansion for 7 or more days demonstrated progressive differentiation which may be associated with functional exhaustion. Our analysis confirmed distinct phenotypic populations were established over this period. However, we did not test if this has a consequence on T cell clonality, cytolytic activity, or IFNγ production. This phenomenon is suggestive of that seen in traditional TIL, however the ideal comparison would be to TIL from the same patients. There are obvious clinical barriers to obtaining metastatic solid tumor as well as MPE from the same patient, but is the subject of future studies. None the less, MPEs present a potential advantage of readily accessing “bulk” T cells with a less differentiated (pre-culture) state for studying tumor reactivity, or possibly ex vivo testing of T cell activating therapies [47].

Collectively, our findings beg the question if T cell repression in an MPE could be reversed. Future studies will explore effects of the immunosuppressive cells and acellular mediators on CD8+ T cells and may inform us of the short-and long-term alterations they influence. Additionally, because the pleural cavity can be controlled (to some degree) with an indwelling catheter, perhaps it indicates a need to drain or modify the composition in order to potentiate immunotherapies so that new tumor reactive T cells can be recruited to a more hospitable environment.

There are several limitations to this study. First, this study was of a small population of patients on a variety of chemo and immune therapies with heterogeneous cancers. All of these may alter the composition of the effusion, including the cells and soluble factors. This may have also altered the response of the CD8+ T cells in the cytotoxicity assays. At the same time, this complex and diverse population is an accurate representation of patients seen in clinical practice who may benefit from advanced immunotherapy. Additionally, we were unable to directly compare the MPE resident T cells to traditional TIL, as the MPE patients were undergoing palliative procedures and solid tumor from these same patients was not available. Future experiments will involve comparisons to TIL and PBMC from either patients undergoing ACT with traditional TIL or other solid tumor resections. CD137/4-1BB and CD134/OX40 expression was not significantly elevated after 24-h of co-culture, bringing into question if the cytotoxicity is MHC restricted. This will be the topic of future studies as unrestricted αβ and γδ T cell and NK cell killing could account for the observed cytotoxicity.

Strategies that activate tumor-reactive T cells for the treatment of patients with advanced solid cancers have transformed the therapeutic landscape. We are only beginning to understand the complex interactions that take place within the tumor environment that may promote tumor growth and ultimately prohibit the control of disease. MPEs are an underutilized resource that is usually discarded, but instead could be studied to understand immunosuppressive factors that can be modified for better effector T cell function with immunotherapy.

4. Materials and Methods

4.1. Collection of Specimens

Informed consent for patient participation in this study was obtained prior to drainage from all patients, and no subjects were under the age of 18. The use of human tissue samples in the experiments described were approved by the institutional review board at the University of Pittsburgh (IRB#PRO16110093). Samples were collected as excess pathologic specimens and experiments were not performed on humans. All methods were carried out in accordance with relevant guidelines and regulations.

A total of 12 MPEs (300 cc–1000 cc) were collected for clinically indicated drainage of symptomatic effusions, either by thoracentesis, or from a temporary or indwelling tunneled catheter. These specimens would otherwise be medical waste. Cell counts were performed prior to sample processing. MPEs were centrifuged to pellet cells, and acellular fluid was collected and stored at −80 °C. The cellular fraction
was then lysed of red blood cells, washed, counted, sorted, and utilized for co-culture assays and phenotypic analysis. All effusions were examined by a cytopathologist to confirm the presence of malignant cells.

### 4.2. T Cell Expansion and Co-Cultures

The cellular component of MPEs were collected and red blood cells removed by hypotonic lysis. CD45\(^-\) non-hematopoietic tumor containing cells and CD45\(^+\)CD8\(^+\) T cells were isolated by negative and positive magnetic bead enrichment, respectively (BioLegend, San Diego, CA, USA). CD14\(^+\) monocytes were isolated from patient matched peripheral blood by positive bead enrichment (BioLegend, San Diego, CA, USA). T cells were cultured for up to 14 days in complete AIM-V media containing 5% human serum supplemented with 6000 IU/mL IL-2 (StemCell Technologies, Vancouver, Canada) or 6000 IU/mL IL-2 with anti-CD3/CD28 T cell activating beads (Dynabeads, LifeTechnologies, Carlsbad, CA, USA; 1:25 microbead to T cell ratio). Anti-CD3/CD28 beads were used to mimic conditions in an expansion protocol for adoptive cell transfer therapy. Media was exchanged every 2–3 days to replenish IL-2. For co-culture assays, the tumor containing portion was the CD45\(^-\) fraction, which contained tumor cells, mesothelial cells, and a small percent of “other” cells. The CD8\(^+\) T cells were derived from the CD45\(^+\) fraction with bead enrichment. MPE-derived T cells were cultured as above for 24 h prior to the addition of either autologous non-hematopoietic tumor containing cells or autologous peripheral blood monocytes. Co-cultures containing a 1:1 ratio of 10\(^5\) T cells with tumor containing cells or monocytes in 96-well flat-bottomed plate were incubated for 24 h. Cell-free supernatant was collected and remaining cells harvested for flow cytometry analysis. Because of limited cells, seven of 84 co-culture conditions were not performed (4 monocyte and 3 tumor co-cultures). For T cell expansion, cells were cultured and/or expanded for 24 h, 7 days, or 11–14 days then cryopreserved for analysis.

### 4.3. LDH Cytotoxicity Assay

Cytotoxicity was measured in cell-free co-culture supernatant using a lactose dehydrogenase (LDH) cytotoxicity assay kit (Pierce, Thermo Scientific, Waltham, MA, USA) per manufacturer’s instructions. Maximum LDH release was determined by treatment of cells (CD45\(^-\) CD8\(^-\) MPE cells or monocytes) with manufacturer’s lysis buffer. Spontaneous LDH release measured from T cells, monocytes, and CD45\(^-\)CD8\(^-\) MPE cells cultured alone was subtracted from corresponding co-culture values. Percent cytotoxicity was calculated as the experimental value minus the T cell spontaneous release value minus the target cell spontaneous release value divided by the target cell maximum release post-lysis value minus target cell spontaneous release control times 100. Assays were performed in duplicate.

### 4.4. IFN\(\gamma\) Elisa

Interferon gamma (IFN\(\gamma\)) release was measured in 50 \(\mu\)L of cell-free co-culture supernatant following T cell co-cultures using an IFN\(\gamma\)-specific ELISA antibody pair and buffer kit (Invitrogen) per manufacturer’s instructions. Assays were performed in duplicate with manufacturer provided IFN\(\gamma\) standard controls.

### 4.5. Flow Cytometry

Immunophenotyping of MPE and matched peripheral blood were performed on freshly isolated samples. Phenotypic characterization of ex vivo expanded CD8\(^+\) T cells was performed at the same time following cryopreservation to eliminate batch effects. All reagents were purchased from BioLegend unless specified. 1–5 \(\times\) 10\(^6\) cells per sample were stained in Cell Staining Buffer using combinations of mAbs specific followed by labeling with amine-reactive viability dye (LiveDead, Molecular Probes, Eugene, OR, USA). To determine leukocyte composition in MPE and blood, cells were labeled with mAbs for: EpCAM (9C4), CD45 (HI30; BD Biosciences, San Jose, CA, USA), CD3 (UCHT1), CD4 (RPA-T4;
Invitrogen, Carlsbad, CA, USA), CD8a (RPA-R8), HLA-DR (L243), CD11b (ICRF-44), CD14 (HCD-14), CD16 (3G8), CD15 (W6D3), CD66b (G10F5; BD Biosciences), CD123 (6H6), CD11c (3.9), CD56 (HCD56; BD Biosciences), CD19 (SJ25C1), and TCR γ/δ (B1). Expanded T cell cultures were analyzed for: CD3 (UCHT1; BD Biosciences), CD4 (RPA-T4), CD8a (RPA-T8), CD45RA (HI100), CD197 (G043H7), CD95 (DX2), CD25 (BC96), CD127 (A019D5), CD152 (BN13; BD Biosciences), CD223 (Bristol-Myers Squibb, New York, NY, USA), CD279 (eBioJ105; eBioscience, San Diego, CA, USA), CD366 (7D3; BD Biosciences), TIGIT (A15153G), CD134 (Ber-ACT35), CD137 (4B4-1; BD Biosciences), CD228 (ISA-3; eBioscience), CD154 (24-31), and CD357 (108-17). Samples were fixed in 1% paraformaldehyde and data were collected on a five laser LSRFortessa (BD Bioscience) or four laser Cytek Aurora spectral cytometer. FlowJo (BD) software was used for conventionally gated data analysis. Lineage for DC identification consisted of CD3+ , CD19+, and CD56+ cells. For computational analysis, samples were analyzed using Cytofkit package for R studio as previously described [25]. Briefly, CD8+ T cells were manually gated as live, single, CD3+ CD4− CD8+ cells using FlowJo. The gating strategy used to measure lymphoid and myeloid cell subsets is shown in Figure S5. Shown is the successive gating strategy used to ultimately visualize individual cell types from sized, single, viable CD45+ leukocytes. Specific data from flow cytometry experiments are available upon request. Preprocessing was performed to generate expression matrix for each sample in a Flow Cytometry Standard (FCS) file. Parameters of interest were selected and FSC files were exported and uploaded into Cytofkit package. FCS files were transformed using automatic logicle transformation (autoLgcl) and merged in to one matrix using ceil. Cells were clustered using Rphenograph and visualized using t-Distributed Stochastic Neighbor Embedding (t-SNE). This is a graph-based partitioning method which dissects nearest-neighbor data into phenotypically coherent populations based on relatedness. Samples were grouped by time points 24 h, 7 days and 11–14 days and displayed using t-SNE. Heatmaps were generated from Rphenograph using the expression heat map option depicting Rphenograph clusters and marker expression per cluster.

4.6. Clinical Chemistries

Clinical chemistries (sodium, potassium, carbon dioxide, glucose, pH, lactate, and lactate dehydrogenase) were obtained from frozen samples of the acellular fraction of malignant pleural effusions through the clinical laboratories at the University of Pittsburgh Medical Center per their protocols.

4.7. Statistical Analysis and Scientific Rigor

All results were expressed as means ± standard error of the mean (SEM) unless otherwise stated. Data were analyzed using non-parametric Mann-Whitney U tests for comparisons of patient groups, unpaired Student’s t-test for analysis of T cell culture experiments, or Spearman rank-order correlation tests performed using GraphPad Prism8 (GraphPad Software, San Diego, CA, USA). For all hypothesis tests, a $p<0.05$ was considered statistically significant.

Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/21/17/6178/s1. Figure S1: Percent of effector cells isolated from the CD45− fractions of the MPE; Figure S2: CD8+ T cell expression of CD137/4-1BB and CD134/OX40 following 24-h of co-culture with the non-hematopoietic tumor containing fraction from MPEs; Figure S3: T cell expansion that occurred after culture with CD3/CD28 microbead activation; Figure S4: T cell phenotypes that resulted after ex vivo culture with and without CD3/CD28 microbeads for 24 h, 7 days, or 11–14 days; Figure S5: Gating strategy for to measure lymphoid and myeloid cell subsets during flow cytometry analysis; Table S1: Functional Activity of 24-h co-cultured CD8+ T cells and autologous CD45+ tumor containing fraction.

Author Contributions: Conceptualization, R.D., O.T.O., J.D.L., U.S.K., A.C.S. and M.T.L.; methodology, R.D., A.C.S., M.T.L.; formal analysis, R.D. and A.C.S.; investigation, R.D., A.C.S., S.H.E., S.E.M., A.T.R., D.L., T.C.B.; resources, O.T.O., U.S.K., J.D.L.; writing—original draft preparation, R.D., S.H.E., S.E.M., A.T.R., D.L., and A.C.S.; writing—review and editing, O.T.O., J.D.L., U.S.K., T.C.B., M.T.L.; funding acquisition, J.D.L. All authors have read and agreed to the published version of the manuscript.
**Funding:** Research reported in this publication was supported by the Susan G. Komen Foundation award CCR15329745 to Adam Soloﬀ and by the National Cancer Institute of the National Institutes of Health under awards R01CA181450 and R01CA206012, as well as the UPMC/ITTC to Michael Lotze. Udai Kammula received funding from the Department of Surgery. Rajeev Dhupar and Adam Soloﬀ also received support from the University of Pittsburgh’s Dean Faculty Advancement Award. This project used the Hillman Cancer Center Cytometry Facility that is supported in part by award P30CA047904. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**Abbreviations**

- **MPE** Malignant pleural effusion
- **ACT** Adoptive cell transfer
- **TAM** Tumor associated macrophage
- **LDH** Lactose dehydrogenase
- **IFNγ** Interferon gamma
- **FCS** Flow cytometry standard
- **t-SNE** t-distributed stochastic neighbor embedding
- **SEM** Standard error of the mean
- **Tregs** Regulatory T cells
- **TIL** Tumor infiltrating lymphocytes

**References**

1. Scharping, N.; Menk, A.V.; Whetstone, R.D.; Zeng, X.; Delgoffe, G.M. Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. *Cancer Immunol. Res.* 2016, 5, 9–16. [CrossRef]
2. Neumann, A.K.; Yang, J.; Biju, M.P.; Joseph, S.K.; Johnson, R.S.; Haase, V.H.; Freedman, B.D.; Turka, L.A. Hypoxia inducible factor 1 regulates T cell receptor signal transduction. *Proc. Natl. Acad. Sci. USA* 2005, 102, 17071–17076. [CrossRef]
3. Prado-García, H.; Romero-García, S.; Castro-Flores, D.A.; Rumbo-Nava, U. Deficient glucose uptake is linked to impaired Glut1 expression upon CD3/CD28 stimulation in memory T cells from pleural effusions secondary to lung cancer. *Scand. J. Immunol.* 2019, 90, e12802. [CrossRef]
4. Chang, C.; Qiu, J.; O’Sullivan, D.; Buck, M.D.; Noguchi, T.; Curtis, J.D.; Chen, Q.; Gindin, M.; Cubin, M.M.; Van Der Windt, G.J.; et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. *Cell* 2015, 162, 1229–1241. [CrossRef]
5. Ho, P.-C.; Bihaniak, J.D.; MacIntyre, A.; Staron, M.; Liu, X.; Amezquita, R.; Tsui, Y.-C.; Cui, G.; Micevic, G.; Perales, J.C.; et al. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. *Cell* 2015, 162, 1217–1228. [CrossRef]
6. Wang, N.; Yang, L.; Yue, D.; Cao, L.; Li, L.; Wang, D.; Ping, Y.; Shen, Z.; Zheng, Y.; Wang, L.; et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. *Cancer Lett.* 2019, 452, 244–253. [CrossRef]
7. Li, L.; Yang, L.; Wang, L.; Zhang, Y.; Yue, D.; Chen, X.; Ping, Y.; Huang, L. Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages. *Int. J. Cancer* 2016, 139, 2261–2269. [CrossRef]
8. Romero-García, S.; Moreno-Altimirano, M.M.B.; Prado-García, H.; Sánchez-García, F.J. Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance. *Front. Immunol.* 2016, 7, 52. [CrossRef]
9. Haas, R.; Smith, J.; Rocher-Ros, V.; Nadkarni, S.; Montero-Melendez, T.; D’Acquisto, F.; Bland, E.J.; Bombardieri, M.; Pitzalis, C.; Perretti, M.; et al. Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. *PLoS Biol.* 2015, 13, e1002202. [CrossRef]
10. Ohue, Y.; Nishikawa, H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? *Cancer Sci.* 2019, 110, 2080–2089. [CrossRef]
11. Kumar, V.; Patel, S.; Teyganov, E.; Gabrilovich, D.I. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. *Trends Immunol.* **2016**, *37*, 208–220. [CrossRef] [PubMed]

12. Pathria, P.; Louis, T.L.; Varner, J.A. Targeting Tumor-Associated Macrophages in Cancer. *Trends Immunol.* **2019**, *40*, 310–327. [CrossRef] [PubMed]

13. Antony, P.A.; Piccirillo, C.A.; Akpinarli, A.; Finkelstein, S.E.; Speiss, P.J.; Surman, D.R.; Palmer, D.C.; Chan, C.-C.; Klebanoff, C.A.; Overwijk, W.W.; et al. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells. *J. Immunol.* **2005**, *174*, 2591–2601. [CrossRef] [PubMed]

14. Donnenberg, A.D.; Luketich, J.D.; Dhupar, R.; Donnenberg, V.S. Treatment of malignant pleural effusions. *Cancer Immunol. Immunother.* **2013**, *62*, 1458–1471. [CrossRef] [PubMed]

15. Murthy, P; Ekeke, C.N.; Russell, K.L.; Butler, S.C.; Wang, Y.; Luketich, J.D.; Soloﬀ, A.C.; Dhupar, R.; Lotze, M.T. Making cold malignant pleural effusions hot: Driving novel immunotherapies. *OncoImmunology* **2019**, *8*, e1554969. [CrossRef]

16. Donnenberg, A.D.; Lu knots, J.D.; Dhupar, R.; Donnenberg, V.S. Treatment of malignant pleural effusions: The case for localized immunotherapy. *J. Immunother. Cancer* **2019**, *7*, 110. [CrossRef]

17. Society, A.T. Management of Malignant Pleural Effusions. *Am. J. Respir. Crit. Care Med.* **2000**, *162*, 187–2001.

18. Chen, Y.-M.; Tsai, C.-M.; Whang-Peng, J.; Perng, R.-P. Double Signal Stimulation was Required for Full Recovery of the Autologous Tumor-Killing Effect of Effusion-Associated Lymphocytes. *Chest* **2002**, *122*, 1421–1427. [CrossRef]

19. Tseng, Y.-H.; Ho, H.-L.; Lai, F.; Luo, Y.-H.; Tseng, Y.-C.; Whang-Peng, J.; Lin, Y.-H.; Chou, T.-Y.; Chen, Y.-M. PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion. *J. Thorac. Oncol.* **2018**, *13*, 447–453. [CrossRef]

20. Prado-García, H.; Romero-García, S.; Puerto-Aquino, A.; Rumbo-Nava, U. The PD-L1/PD-1 pathway promotes dysfunction, but not “exhaustion”, in tumor-responding T cells from pleural effusions in lung cancer patients. *Cancer Immunol. Immunother.* **2017**, *65*, 87–776. [CrossRef]

21. Scherpereel, A.; Grigoriu, B.; Noppen, M.; Gey, T.; Chahine, B.; Baldacci, S.; Trauet, J.; Copin, M.-C.; Dessaint, J.-P.; Porte, H.; et al. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid. *BMC Cancer* **2013**, *13*, 324. [CrossRef] [PubMed]

22. Atanackovic, D.; Block, A.; de Weerth, A.; Faltz, C.; Hossfeld, D.K.; Hegewisch-Becker, S. Characterization of Effusion-Infiltrating T Cells: Benign versus Malignant Effusions. *Clin. Cancer Res.* **2004**, *10*, 2600–2608. [CrossRef] [PubMed]

23. Khanna, S.; Thomas, A.; Abate-Daga, D.; Zhang, J.; Morrow, B.; Steinberg, S.M.; Orlandi, A.; Ferroni, P.; Schlam, J.; Ferroni, P.; et al. Malignant Mesothelioma Effusions Are Infiltrated by CD8+ T Cells Highly Expanding PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. *J. Thorac. Oncol.* **2016**, *11*, 1993–2005. [CrossRef] [PubMed]

24. Prado-García, H.; Aguilar-Cazares, D.; Flores-Vergara, H.; Mandoki, J.J.; López-González, J.S. Effector, memory and naïve CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. *Lung Cancer* **2005**, *47*, 361–371. [CrossRef] [PubMed]

25. Chen, H.; Lau, M.C.; Wong, M.T.; Newell, E.W.; Poidinger, M.; Chen, J. Cytofkit: A Bioconductor Package for an Integrated Mass Cytometry Data Analysis Pipeline. *PLoS Comput. Biol.* **2016**, *12*, e1005112. [CrossRef]

26. Poch, M.; Hall, M.; Joerger, A.; Kodumudi, K.; Beatty, M.; Innamarato, P.P.; Bunch, B.L.; Fishman, M.N.; Zhang, J.; Sexton, W.J.; et al. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. *Oncoimmunology* **2018**, *7*, e1476816. [CrossRef]

27. Chandran, S.S.; Somerville, R.P.T.; Yang, J.C.; Sherry, R.M.; Klebanoff, C.A.; Goff, S.L.; Wunderlich, J.R.; Danforth, D.N.; Zlot, D.; Paria, B.C.; et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: A single-centre, two-stage, single-arm, phase 2 study. *Lancet Oncol.* **2017**, *18*, 792–802. [CrossRef]

28. Ben-Avi, R.; Farhi, R.; Ben-Nun, A.; Gorodner, M.; Greenberg, E.; Markel, G.; Schachter, J.; Itzhaki, O.; Besser, M.J. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. *Cancer Immunol. Immunother.* **2018**, *67*, 1221–1230. [CrossRef]
29. Friedman, K.M.; Prieto, P.A.; Devillier, L.E.; Gross, C.A.; Yang, J.C.; Wunderlich, J.R.; Rosenberg, S.A.; Dudley, M.E. Tumor-specific CD4+ Melanoma Tumor-Infiltrating Lymphocytes. *J. Immunother.* 2012, 35, 400–408. [CrossRef]

30. Pasetto, A.; Gros, A.; Robbins, P.F.; Deniger, D.C.; Prickett, T.D.; Matus-Nicodemos, R.; Douek, D.C.; Howie, B.; Robins, H.; Parkhurst, M.R.; et al. Tumor- and Neoantigen- Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor. *Cancer Immunol. Res.* 2016, 4, 734–743. [CrossRef]

31. Gros, A.; Robbins, P.F.; Yao, X.; Li, Y.F.; Turcotte, S.; Tran, E.; Wunderlich, J.R.; Mixon, A.; Farid, S.; Dudley, M.E.; et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. *J. Clin. Investig.* 2014, 124, 2246–2259. [CrossRef] [PubMed]

32. Delong, P.; Carroll, R.G.; Henry, A.C.; Tanaka, T.; Ahmad, S.; Leibowitz, M.S.; Sterman, D.H.; June, C.H.; Albelda, S.M.; Vonderheide, R.H. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. *Cancer Biol. Ther.* 2005, 4, 342–346. [CrossRef]

33. Prado-Garcia, H.; Romero-Garcia, S.; Rumbo-Nava, U.; Lopez-Gonzalez, J.S. Predominance of Th17 over regulatory T-cells in pleural effusions of patients with lung cancer implicates a proinflammatory profile. *Anticancer. Res.* 2015, 35, 1529–1535. [PubMed]

34. Rivadeneira, D.B.; Delgoffe, G.M. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. *Clin. Cancer Res.* 2018, 24, 2473–2481. [CrossRef] [PubMed]

35. Ding, J.; Karp, J.E.; Emadi, A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. *Cancer Biomark.* 2017, 19, 353–363. [CrossRef] [PubMed]

36. Husain, Z.; Huang, Y.; Seth, P.; Sukhatme, V.P. Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells. *J. Immunol.* 2013, 191, 1486–1495. [CrossRef]

37. Fischer, K.; Hoffmann, P.; Voelkl, S.; Meidenbauer, N.; Ammer, J.; Edinger, M.; Gottfried, E.; Schwarz, S.; Rothe, G.; Hoves, S.; et al. Inhibitory effect of tumor cell–derived lactic acid on human T cells. *Blood* 2007, 109, 3812–3819. [CrossRef]

38. Hernandez, A.L.; Kitz, A.; Wu, C.; Lowther, D.E.; Rodriguez, D.M.; Vudattu, N.; Deng, S.; Herold, K.C.; Kuchroo, V.K.; Kleineveldt, M.; et al. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. *J. Clin. Investig.* 2015, 125, 4212–4222. [CrossRef]

39. Willebrand, R.; Kleineveldt, M. The role of salt for immune cell function and disease. *Immunology* 2018, 154, 346–353. [CrossRef]

40. Dudley, M.E.; Gross, C.A.; Langhan, M.M.; Garcia, M.R.; Sherry, R.M.; Yang, J.C.; Chan, A.; Hughes, M.S.; Citrin, D.E.; et al. CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. *Clin. Cancer Res.* 2010, 16, 6122–6131. [CrossRef]

41. Dudley, M.E.; Wunderlich, J.R.; Shelton, T.E.; Even, J.; Rosenberg, S.A. Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients. *J. Immunother.* 2003, 26, 332–342. [CrossRef]

42. Fernandez-Poma, S.M.; Salas, D.; Lozano, T.; Casesas, N.; Riezu-Boj, J.I.; Mancheño, U.; Elizalde, E.; Alignani, D.; Zubeldia, N.; Otano, I.; et al. Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. *Cancer Res.* 2017, 77, 3672–3684. [CrossRef]

43. Hall, M.; Liu, H.; Malafa, M.P.; Centeno, B.A.; Hodul, P.J.; Pimiento, J.M.; Pilon-Thomas, S.; Sarndaik, A. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. *J. Immunother. Cancer* 2016, 4, 61. [CrossRef] [PubMed]

44. Hurtado, M.O.; Wolbert, J.; Fisher, J.; Flutter, B.; Stafford, S.; Barton, J.; Jain, N.; Barone, G.; Majani, Y.; Anderson, J. Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. *PloS ONE* 2019, 14, e0216373. [CrossRef] [PubMed]

45. Poschke, I.C.; Hassel, J.C.; Ehrenfried, A.R.; Lindner, K.A.; Heras-Murillo, I.; Appel, L.M.; Lehmann, J.; Lövgren, T.; Wickström, S.L.; Lauenstein, C.; et al. The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones. *Clin. Cancer Res.* 2020. [CrossRef] [PubMed]
46. Tran, K.Q.; Zhou, J.; Durflinger, K.H.; Langhan, M.M.; Shelton, T.E.; Wunderlich, J.R.; Robbins, P.F.; Rosenberg, S.A.; Dudley, M.E. Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy. *J. Immunother.* 2008, 31, 742–751. [CrossRef]

47. Shen, X.; Zhou, J.; Hathcock, K.S.; Robbins, P.; Powell, D.J.; Rosenberg, S.A.; Hodes, R.J. Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere Length. *J. Immunother.* 2007, 30, 123–129. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).